| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 10966352 | Vaccine | 2013 | 9 Pages |
Abstract
HEPLISAV is a cost-effective option to provide high rates of seroprotection and early seroprotection across a range of populations from health care workers to patients with chronic or end stage kidney disease.
Keywords
QALYinternational travelersquality adjusted life-yearICERHBsAgASRHCCantibody to hepatitis B surface antigenHepatitis B surface antigenDiabeteschronic kidney diseaseEnd-stage renal diseaseCost-effectiveness analysisSPRFulminant hepatic failureAnti-HBsAge-standardized rateIncremental cost-effectiveness ratioHBVHepatitis BVaccinehepatitis B virusHepatocellular carcinoma
Related Topics
Life Sciences
Immunology and Microbiology
Immunology
Authors
Renee Kim Kuan, Robert Janssen, William Heyward, Sean Bennett, Robert Nordyke,